R
Royalty Pharma plc (RPRX)
NMS – Real Time Price. Currency in USD
51.70
+0.05 (0.10%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
51.70
+0.05 (0.10%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.66 | 6.05 | 10 | |
| Quick ratio | 2.66 | 5.63 | 10 | |
| Debt to Equity | 1.30 | 0.30 | 5.0 | |
| Debt to Assets | 0.45 | 1.04 | 5.0 | |
| Interest coverage | 6.75 | -16.91 | 10 | |
| Weighted average score | 8.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 2.24B | 2.35B | 2.26B | 2.38B | 2.44B |
| Gross Profit | 2.23B | N/A | N/A | 2.37B | 1.86B |
| Operating Income | 923M | 1.49B | 1.29B | 1.56B | 1.66B |
| Net Income | 43M | 1.13B | 859M | 771M | 827M |
| EBITDA | 929M | 1.49B | 1.29B | 1.56B | 1.66B |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 8.6 | 11.85 | 6.5 |
| Next quarter | 7.49 | -3.76 | 3.0 |
| Current year | 6.13 | 6.24 | 5.0 |
| Next year | 7.45 | 9.59 | 5.5 |
| Weighted average score | 5.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 1.38 | 37.71 | -11.56 | -8.59 | 3.8 |
| Y/Y | 10.97 | 23.12 | 73.03 | 20.27 | 9.3 |
| 3y average | 2.15 | 838.32 | 10.27 | 8.82 | 6.5 |
| 5y average | 2.41 | 477.09 | 15.29 | 6.23 | 6.8 |
| Weighted average score | 6.6 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 2.42 | 2.42 | 7.0 |
| Payout ratio | 17.18 | 17.18 | 3.0 |
| 5-year dividend growth rate | 24.01 | 24.01 | 10 |
| Years of dividend increase | 5.00 | 5.00 | 5.0 |
| Weighted average score | 6.3 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Wide | 8.0 |
| Intangible assets | Wide | 8.0 |
| Switching costs | Medium | 7.0 |
| Network effect | Medium | 6.0 |
| Economies of scale | Wide | 8.0 |
| Weighted average score | 7.4 | |
Total debt $9.0B significantly exceeds cash reserves ($586.4M), raising financial stability concerns
Total current assets $1.4B exceed Total current liabilities $535.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.9) is near the industry average, reflecting balanced leverage
Interest coverage ratio (7x) indicates the company easily manages its debt payments
The company generates positive free cash flow $760.5M, supporting its financial health